D1

23. (Twice amended) A method of inhibiting cell growth *in vitro*, said method comprising transfecting said cell with a polynucleotide, wherein said polynucleotide is between 8 and 50 nucleotides in length and said between 8 and 50 nucleotides are complementary to a mRNA molecule encoding SEQ ID NO:2, wherein said polynucleotide is not complementary to or identical to contiguous nucleotides between nucleotide 692 and 1385 of SEQ ID NO:1.

D2

28. (Amended) A method of inhibiting the activity of Nogo B in a cell *in vitro*, said method comprising treating said cell with an antisense oligonucleotide wherein said antisense oligonucleotide hybridizes with a polynucleotide encoding Nogo B, wherein said polynucleotide is not complementary to or identical to contiguous nucleotides between nucleotide 692 and 1385 of SEQ ID NO:1.

29. (Amended) A method of inhibiting the activity of Nogo B in a cell *in vitro*, said method comprising treating said cell with a ribozyme capable of cleaving mRNA encoding said Nogo B, wherein said ribozyme does not cleave mRNA complementary to or identical to nucleotides 692-1385 of SEQ ID NO:1.

REMARKS

The Examiner is requested to contact the undersigned representative if any additional information is required.

Claims 23, 28 and 29 have been amended, without prejudice or disclaimer, to delete the term "or *ex vivo*."

During a telephone conference with the undersigned representative on March 29, 2002, Examiner Zara requested that applicants point out the polynucleotide region that corresponds to the amino acid numbers indicated in Claim 1, as filed on November 21, 2001.

These regions are as follows:

Claim	Amino acid sequence, SEQ ID NO:2	Corresponding nucleotides in SEQ ID NO:1
1(a)	1-373	1-1121
1(b)	2-373	4-1121
1(c)	1-197	1-596
1(c)	236-373	711-1121
1(d)	1-288	1-869
1(d)	336-373	1013-1121
1(e)	1-197	1-596
1(e)	236-288	711-869
1(e)	336-373	1013-1121
1(e)	197-236	596-711
1(f)	1-187	1-566
1(g)	2-187	4-566
1(h)	1-198	1-599

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned **"Version With Markings to Show Changes Made."**

All of the claims remaining in the application are now clearly allowable. Favorable consideration and a Notice of Allowance are earnestly solicited.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Jane E. R. Potter
Registration No. 33,332

(JEP:cew) #271327

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 23, 28 and 29 have been amended as follows:

23. (Twice amended) A method of inhibiting cell growth *in vitro ~~or ex vivo~~*, said method comprising transfecting said cell with a polynucleotide, wherein said polynucleotide is between 8 and 50 nucleotides in length and said between 8 and 50 nucleotides are complementary to a mRNA molecule encoding SEQ ID NO:2, wherein said polynucleotide is not complementary to or identical to contiguous nucleotides between nucleotide 692 and 1385 of SEQ ID NO:1.

28. (Amended) A method of inhibiting the activity of Nogo B in a cell *in vitro ~~or ex vivo~~*, said method comprising treating said cell with an antisense oligonucleotide wherein said antisense oligonucleotide hybridizes with a polynucleotide encoding Nogo B, wherein said polynucleotide is not complementary to or identical to contiguous nucleotides between nucleotide 692 and 1385 of SEQ ID NO:1.

29. (Amended) A method of inhibiting the activity of Nogo B in a cell *in vitro ~~or ex vivo~~*, said method comprising treating said cell with a ribozyme capable of cleaving mRNA encoding said Nogo B, wherein said ribozyme does not cleave mRNA complementary to or identical to nucleotides 692-1385 of SEQ ID NO:1.

(JEP:cew) #271327